Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects

doi:10.3748/wjg.v20.i16.4526

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 16

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11143)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

580

WORD

349

HTML

7777

Figures (1-6)

157

Tables (1-3)

130

Sum=8993

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1207

Download

943

Sum=2150

Apr 28, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 28, 2014; 20(16): 4526-4535
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4526

Table 3 Overview of the phase II and III compounds and their targets

Compounds	Type of compound	Target(s)	Clinical phase
Dacomitinib (PF-00299804, Pfizer)	Irreversible pan-HER TKI	HER1 (EGFR) and HER2	II
Afatinib (Gilotrif, Boehringer Ingelheim)	Irreversible pan-HER TKI	HER1 (EGFR), HER2, and HER4	II
Pertuzumab (Perjeta, Roche/Genentech)	mAb	HER2 (subdomain II), HER2 hetero dimerization	II/III
Ado-trastuzumab emtansine (Kadcyla, Roche/Genentech)	ADC	HER2 (subdomain IV)	II/III
Lapatinib (Tyverb/Tykerb, GSK)	Reversible pan-HER TKI	HER1 (EGFR) and HER2	III

TKI: Tyrosine kinase inhibitors; mAb: Monoclonal antibody; ADC: Antibody-drug conjugate.

Citation: Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535
URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4526.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4526